Literature DB >> 2915243

Reversible acute and subacute myelopathy in patients with dural arteriovenous fistulas. Foix-Alajouanine syndrome reconsidered.

G R Criscuolo1, E H Oldfield, J L Doppman.   

Abstract

Acute or subacute neurological deterioration without evidence of hemorrhage in a patient with a spinal arteriovenous (AV) malformation has been referred to as "Foix-Alajouanine syndrome." This clinical entity has been considered to be the result of progressive vascular thrombosis resulting in a necrotic myelopathy; it has therefore been thought to be largely irreversible and hence untreatable. The authors report five patients with dural AV fistulas who presented in this manner, and who improved substantially after embolic and surgical therapy. The outcome of these patients indicates that acute and subacute progression of myelopathy in cases of spinal dural AV fistulas may be caused by venous congestion and not necessarily by thrombosis. Therefore, a clinical diagnosis of Foix-Alajouanine syndrome is of little practical use, as spinal cord dysfunction from venous congestion is a potentially reversible process whereas thrombotic infarction is not. This diagnosis may result in suboptimal management. The recognition of nonhemorrhagic acute or subacute myelopathy as a complication of a spinal dural AV fistula is important since what appears to be irreversible cord injury is often treatable by standard surgical techniques.

Entities:  

Mesh:

Year:  1989        PMID: 2915243     DOI: 10.3171/jns.1989.70.3.0354

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  19 in total

Review 1.  Non-neoplastic intramedullary pathology. Diagnostic dilemma: to Bx or not to Bx.

Authors:  T H Schwartz; P C McCormick
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Secondary clinical deterioration after successful embolization of a spinal dural arteriovenous fistula: a plea for prophylactic anticoagulation.

Authors:  J Knopman; W Zink; A Patsalides; H A Riina; Y P Gobin
Journal:  Interv Neuroradiol       Date:  2010-07-19       Impact factor: 1.610

3.  Preangiographic evaluation of spinal dural arteriovenous fistulas with elliptic centric contrast-enhanced MR Angiography and effect on radiation dose and volume of iodinated contrast material.

Authors:  Patrick H Luetmer; John I Lane; Julie R Gilbertson; Matt A Bernstein; John Huston; John L D Atkinson
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

4.  Spinal dural arteriovenous malformations with perimedullary drainage. Indications and results of surgery in 30 cases.

Authors:  K L Mourier; F Gelbert; A Rey; E Assouline; B George; D Reizine; J J Merland; J Cophignon
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

5.  Magnetic resonance imaging in spinal emergency.

Authors:  D Koch; A K Wakhloo; V van Velthoven
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

6.  Spinal dural arteriovenous fistulas: a plea for neurosurgical treatment.

Authors:  B C Huffmann; J M Gilsbach; A Thron
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

7.  Angiographically proven cervical venous engorgement: a possible concurrent cause in the pathophysiology of Hirayama's myelopathy.

Authors:  Elisa F Ciceri; Luisa Chiapparini; Alessandra Erbetta; Laura Longhi; Benedetta Cicardi; Nicoletta Milani; Carlo Lazzaro Solero; Mario Savoiardo
Journal:  Neurol Sci       Date:  2010-09-21       Impact factor: 3.307

Review 8.  Spinal vascular malformations.

Authors:  Timo Krings; Michael Mull; Joachim M Gilsbach; Armin Thron
Journal:  Eur Radiol       Date:  2004-10-22       Impact factor: 5.315

9.  Spinal cord oedema due to venous stasis.

Authors:  F C Henderson; H A Crockard; J M Stevens
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

10.  Recurrent myelitis.

Authors:  L Pandit; S Rao
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.